Back to Search
Start Over
The effect of the 2019 ESC/EAS dyslipidaemia guidelines on low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS EuroPath IV project.
- Source :
-
Vascular pharmacology [Vascul Pharmacol] 2023 Feb; Vol. 148, pp. 107141. Date of Electronic Publication: 2023 Jan 07. - Publication Year :
- 2023
-
Abstract
- Aims: To evaluate the effect of the ESC/EAS 2019 dyslipidaemia guidelines on patient management of lipid-lowering therapy in patients with acute coronary syndrome (ACS), through a survey designed to compare post-ACS patient management in 2022 with that in 2018.<br />Methods: Online questionnaires focused on lipid profile and medications were used to gather data from 2650 ACS patients in 6 European countries, treated between March-June 2022 (ACS EuroPath IV survey). These data were compared with data collected from 2650 patients who participated in the ACS EuroPath I survey (conducted in 2018).<br />Results: Lipid testing was performed in 90% of patients and was done sooner after admission in 2022 versus 2018 (mean 1.4 vs 1.7 days). Increased testing for non-HDL-C, lipoprotein(a), and ApoB was observed over time. At discharge, most patients (≥90%) were receiving lipid-lowering therapy. Prescribing patterns differed, with a higher proportion of patients receiving statin plus ezetimibe combination therapy in 2022 versus 2018 (34% vs 13%). LDL-C levels were lower in 2022 versus 2018 at admission and at 1st, 2nd and 3rd post-discharge follow-up points. More patients achieved low-density lipoprotein cholesterol (LDL-C) goals in 2022 versus 2018 at the first follow-up (average 14 vs 16 weeks since discharge; <70 mg/dL [1.8 mmol/L]: 34% vs 20%; <55 mg/dL [1.4 mmol/L]: 18% vs 10%) and at subsequent follow-up points.<br />Conclusion: LDL-C goal achievement has improved since the release of the 2019 guidelines, but lipid management in post-ACS patients remains suboptimal.<br />Competing Interests: Declaration of Competing Interest UL has received honoraria, lecture fees or research grants from Amgen, Daiichi Sankyo, Novartis and Sanofi. ALC has received honoraria, lecture fees or research grants from: AstraZeneca, Aegerion, Amryt, Amarin, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Medscape, Mylan, Merck, Menarini, Novartis, Peer Voice, Pfizer, Recordati, Regeneron, Sandoz, Sanofi and The Corpus. The work of ALC relevant to this publication is supported by Ministero della salute Ricerca corrente. RDC has received honoraria, lecture fees or research grants from Boehringer Ingelheim, Bayer, BMS/Pfizer, Daiichi Sankyo, Roche, Novartis, AstraZeneca, Milestone, Menarini, Guidotti, Lilly, Merck and Portola. AS has received honoraria, lecture fees or research grants from Amgen, Daiichi Sankyo, Ferrer, Getinge, Novartis, Pfizer, Sanofi and Zoll. AZ has received honoraria, consulting or lecture fees from Sanofi, Amgen and Novartis. FS has received research grants from and/or was speaker (with or without lecture fees) on a.o. (CME accredited) meetings sponsored by Amgen, Bayer, Novartis, Novo Nordisk, Sanofi Aventis, Recordati, Servier, Mylan and AstraZeneca. JWJ/his department has received research grants from and/or was speaker (with or without lecture fees) on a.o. (CME accredited) meetings sponsored by Amarin, Amgen, Athera, Biotronik, Boston Scientific, Dalcor, Daiichi Sankyo, Lilly, Medtronic, Merck-Schering-Plough, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Aventis, the Netherlands Heart Foundation, CardioVascular Research the Netherlands (CVON), the Netherlands Heart Institute and the European Community Framework KP7 Programme.<br /> (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
- Subjects :
- Humans
Cholesterol, LDL
Goals
Aftercare
Treatment Outcome
Patient Discharge
Acute Coronary Syndrome diagnosis
Acute Coronary Syndrome drug therapy
Hydroxymethylglutaryl-CoA Reductase Inhibitors adverse effects
Dyslipidemias diagnosis
Dyslipidemias drug therapy
Dyslipidemias epidemiology
Anticholesteremic Agents adverse effects
Subjects
Details
- Language :
- English
- ISSN :
- 1879-3649
- Volume :
- 148
- Database :
- MEDLINE
- Journal :
- Vascular pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 36626974
- Full Text :
- https://doi.org/10.1016/j.vph.2023.107141